STANMORE, England, April 15, 2013 /PRNewswire/ -- The Royal National Orthopaedic Hospital (RNOH), the largest musculoskeletal orthopedic hospital in the United Kingdom and a leader in the field of orthopedics and spine, and SpineMark Corporation, a United States-based developer of spine centers of excellence and spine research organizations, have announced a joint agreement to develop a spine research unit within RNOH called Spinal Research Stanmore (SRS).
Under the agreement, RNOH will provide administrative support and clinicians to meet the demands of industry and internal study goals including recruiting patients and investigators. RNOH and SpineMark will seamlessly oversee clinical trials and management of the unit. SpineMark will provide the development, marketing, governance, contracting, oversight, physician peer mentoring — provided by its medical advisory board OrbiSpine — and support for SRS, including any necessary training for new spine-dedicated clinical research coordinators and staff associated with the unit.
The short-term SRS objectives include significant research growth in the unit by supporting sponsor initiated clinical and post market studies as well as the creation of SRS retrospective and prospective study groups to evaluate key trends, techniques, outcomes and diagnostic data from RNOH patients.
"RNOH's goal is to formalize and grow its spinal research profile and accomplishments, and our partnership with SpineMark will help us advance these objectives," says Rob Hurd, CEO of RNOH. "We are looking forward to seeing the unit develop and expand throughout the year."
"RNOH has demonstrated an impressive commitment to spinal clinical research and SpineMark is pleased to serve as its partner through the establishment of SRS," says Marcy Rogers, President and CEO of SpineMark. "We expect our spine research model to serve as a significant driver of growth for the unit."
SpineMark continues to broaden its international presence with the partnership with RNOH. "The partnership with RNOH is an exciting development for SpineMark," says Rogers. "There is an ever growing global demand for new spinal treatments and research, and we are looking forward to introducing SRS as a premier spinal research site for sponsors in the field."
SOURCE SpineMark Corporation